Related Experiment Video
Updated: Jun 20, 2026

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
Published on: July 7, 2020
Infections caused by Gram-positive bacteria: a review of the global challenge
Neil Woodford1, David M Livermore
1Antibiotic Resistance Monitoring and Reference Laboratory, Centre for Infections, Health Protection Agency, London, UK. neil.woodford@hpa.org.uk
Abstract:
Infections caused by multidrug-resistant Gram-positive bacteria represent a major public health burden, not just in terms of morbidity and mortality, but also in terms of increased expenditure on patient management and implementation of infection control measures. Staphylococcus aureus and Enterococcus spp. are established pathogens in the hospital environment, and their frequent multidrug resistance complicates therapy. The archetypal hospital "superbug", methicillin-resistant S. aureus (MRSA), regularly attracts mass-media interest and, in many countries, there is political pressure to reduce MRSA infection rates, with some progress now being made in the United Kingdom and the United States. To compound these established problems, we have witnessed the emergence and spread of virulent clones of MRSA in the community, and of Clostridium difficile in hospitals. Multidrug-resistant Streptococcus pneumoniae clones are major community pathogens in many parts of the world, but are now being challenged by new conjugate vaccines. Using combinations of molecular epidemiological tools, which characterize the resistant isolates and their resistance determinants, scientists can track highly successful bacterial strains at local, national, and international levels. These methods have provided new insights into the evolution of key pathogens, and this information may aid the design of control strategies and vaccines. In addition, the development of new antimicrobials including oxazolidinones, lipopeptides, glycylcyclines, ketolides, and new generations of fluoroquinolones, antistaphylococcal b-lactams, and glycopeptides must remain a high priority for the continued effective treatment of infections caused by resistant strains. So far, resistance to these newer agents is identified rarely in surveillance programs, but occasional reports of resistance causing therapeutic failure (e.g., with linezolid, daptomycin, telithromycin, or newer fluoroquinolones) give cause for concern. The emergence of antibiotic resistance is inevitable, but we must seek to decrease its impact and prolong the effectiveness of the agents available to us.
Insights
Multidrug-resistant Gram-positive bacteria pose a significant public health threat. Molecular epidemiology aids in tracking resistant strains and informing control strategies for these challenging infections.
Area of Science:
- Microbiology
- Epidemiology
- Infectious Diseases
Background:
- Multidrug-resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus spp., cause significant morbidity, mortality, and healthcare costs.
- The emergence of virulent MRSA clones in the community and Clostridium difficile in hospitals exacerbates the challenge of hospital-acquired infections.
- Multidrug-resistant Streptococcus pneumoniae remains a major community pathogen, though new vaccines offer a potential countermeasure.
Purpose of the Study:
- To highlight the public health burden of multidrug-resistant Gram-positive bacterial infections.
- To discuss the role of molecular epidemiology in tracking and understanding the evolution of resistant bacterial strains.
- To emphasize the critical need for developing new antimicrobial agents and strategies to combat antibiotic resistance.
Main Methods:
- Utilizing molecular epidemiological tools to characterize resistant bacterial isolates and their resistance determinants.
- Employing surveillance programs to monitor the prevalence of resistance to existing and novel antimicrobial agents.
- Analyzing trends in the emergence and spread of virulent bacterial clones globally.
Main Results:
- Molecular epidemiology provides insights into the evolution and dissemination of key resistant pathogens.
- New antimicrobial agents (e.g., oxazolidinones, lipopeptides) show promise, with resistance currently identified rarely.
- Occasional therapeutic failures due to resistance to newer agents underscore the ongoing threat.
Conclusions:
- Effective control strategies and vaccine development can be informed by understanding bacterial evolution and resistance patterns.
- Continued development of novel antimicrobials is essential to maintain treatment options against resistant infections.
- While antibiotic resistance is inevitable, proactive measures can mitigate its impact and preserve the efficacy of available treatments.
Related Concept Videos
Development of Antibiotic Resistance
Clinical Significance of Antibiotic Resistance
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies. Common...
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Urinary Tract Infection II: Pathophysiology
